Methods and compositions comprising trigonelline for the treatment of muscle weakness and renal dysfunction

Trigonelline administration addresses muscle wasting and renal dysfunction by enhancing muscle mass and function, stabilizing renal function, and slowing disease progression, offering a comprehensive treatment for chronic kidney disease.

JP2026523201APending Publication Date: 2026-07-13SOCIETE DES PRODUITS NESTLE SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025574733
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-29
Filing Date
2024-06-27
Publication Date
2026-07-13

AI Technical Summary

Technical Problem

Muscle wasting and renal dysfunction, particularly in chronic kidney disease, lead to significant morbidity and mortality due to irreversible kidney damage and muscle mass loss, with current treatments lacking effective solutions for slowing progression and improving muscle function.

Method used

Administration of trigonelline or its pharmaceutically acceptable salts to subjects, either enterally or parenterally, in the form of nutritional compositions or unit dosage forms, to improve lean muscle mass, reduce glomerular damage, and enhance muscle fiber size and nicotinamide adenine dinucleotide levels.

Benefits of technology

Trigonelline effectively stabilizes renal function, maintains muscle mass, improves muscle endurance and efficiency, and reduces muscle atrophy, while slowing the progression of glomerular filtration rate and reducing hyalinization damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026523201000004
    Figure 2026523201000004
  • Figure 2026523201000005
    Figure 2026523201000005
  • Figure 2026523201000006
    Figure 2026523201000006
Patent Text Reader

Abstract

This disclosure relates to methods and compositions comprising trigonelline for treating or preventing diseases or conditions generally associated with muscle attenuation and / or renal dysfunction. Furthermore, it relates to methods and compositions comprising trigonelline for slowing progression in glomerular filtration rate (GFR), and / or reducing glomerular damage due to hyalinization, and / or improving muscle lean mass. Furthermore, methods and compositions comprising trigonelline for improving muscle lean mass and / or improving muscle fiber size are disclosed. Methods and compositions comprising trigonelline for improving the level of at least one nicotinamide adenine dinucleotide are also disclosed. Methods and compositions comprising trigonelline for increasing muscle stem cells and / or mitigating the decrease in muscle stem cells are also disclosed.
Need to check novelty before this filing date? Find Prior Art